DxVx signs contract for vaccine delivery material and lipid nanoparticle process development
DxVx has signed a research contract with the Pohang University of Science and Technology (POSTECH) Industry-University Cooperation Foundation to advance global technologies for vaccine and new drugs development.
On 1 August, DxVx made an official announcement regarding its new research contract with the POSTECH Industry-University Cooperation Foundation. This agreement primarily focused on enhancing the membrane process used in the production of lipid nanoparticles containing genes therapies and vaccines, as well as the manufacturing process for color nanoparticles used in diagnosis.
Through this joint research, DxVx anticipates to acquire cutting-edge global technologies associated with the manufacturing techniques and equipment for lipid nanoparticles. These nanoparticles serve as carriers for delivering messenger ribohexane (mRNA) vaccines and treatment to specific tissues and cells.
Lipid nanoparticles serve as delivery vehicles that safely transport mRNA to target tissues and cells. This technology is a cornerstone of the drug delivery system, aiding in the effective delivery of vaccines and novel drug compounds to the human body, thereby allowing the expression of their efficacy. The company has outlined its strategy to secure proprietary technology through research and development, concurrently pursuing international patents for geological nanoparticles, traditionally dominated by global pharmaceutical enterprises.
A company official predicted, "By securing the technology for the necessary manufacturing equipment, as well as manufacturing and mass production technology for lipid nanoparticles, it will be applicable in future vaccine production processes."
This three-year project builds upon a joint-research between Coree Group and POSTECH over the last year. Going forward, DXVx will continue the research on behalf of Coree Group from this year. Notably, the research project has made significant progress in patent applications, including a 'manufacturing method of lipid nanoparticles for mRNA delivery to enhance mRNA delivery efficiency' and a chamber device for manufacturing lipid nanoparticles.
Meanwhile, Coree Group has already been engaged in a collaborative research endeavor with Sichuan University in China since 2021. The focus of this initiative is the development of nucleic acid vaccine delivery system and platforms.
Source: Financial News